R Buttery1, H Monaghan, D M Salter, T Sethi. 1. Division of Pathology, School of Sciences and Molecular Medicine, University of Edinburgh, Edinburgh, UK.
Abstract
AIMS: To compare the histological expression of galectin-3 in different lung cancers, including small-cell lung cancer (SCLC) and non-small-cell lung cancer (NSCLC). Lung cancer is the leading cause of cancer deaths in the UK. Galectin-3 is a beta-galactoside binding protein with a controversial role in malignant transformation. SCLC metastasizes early and is initially chemosensitive; NSCLC metastasizes later, offering the chance of surgical cure, but is much less chemosensitive. Mixed tumours present a diagnostic and therapeutic problem, with a poorer response to therapy. Insight into the cellular mechanisms that govern metastasis and chemoresistance will profoundly influence the future management of this disease. METHODS AND RESULTS: In this study the histological expression of galectin-3 was assessed in a panel of lung tumour specimens, using the indirect streptavidin-biotin method. A striking difference in galectin-3 expression was observed between tumours, with high expression in NSCLC (42/47 samples) and low expression in SCLC (negative in 13/18, weak in 5/18). CONCLUSION: This differential expression of galectin-3 between histological types of lung carcinoma suggests that galectin-3 may have an important influence on tumour cell adhesion, apoptosis and the response of tumours to chemotherapy.
AIMS: To compare the histological expression of galectin-3 in different lung cancers, including small-cell lung cancer (SCLC) and non-small-cell lung cancer (NSCLC). Lung cancer is the leading cause of cancer deaths in the UK. Galectin-3 is a beta-galactoside binding protein with a controversial role in malignant transformation. SCLC metastasizes early and is initially chemosensitive; NSCLC metastasizes later, offering the chance of surgical cure, but is much less chemosensitive. Mixed tumours present a diagnostic and therapeutic problem, with a poorer response to therapy. Insight into the cellular mechanisms that govern metastasis and chemoresistance will profoundly influence the future management of this disease. METHODS AND RESULTS: In this study the histological expression of galectin-3 was assessed in a panel of lung tumour specimens, using the indirect streptavidin-biotin method. A striking difference in galectin-3 expression was observed between tumours, with high expression in NSCLC (42/47 samples) and low expression in SCLC (negative in 13/18, weak in 5/18). CONCLUSION: This differential expression of galectin-3 between histological types of lung carcinoma suggests that galectin-3 may have an important influence on tumour cell adhesion, apoptosis and the response of tumours to chemotherapy.
Authors: Tamara Murmann; Carmen Carrillo-García; Nadine Veit; Cornelius Courts; Alexander Glassmann; Viktor Janzen; Burkhard Madea; Markus Reinartz; Anne Harzen; Michael Nowak; Sven Perner; Jochen Winter; Rainer Probstmeier Journal: PLoS One Date: 2014-02-28 Impact factor: 3.240
Authors: Christoph-A von Klot; Mario W Kramer; Inga Peters; Joerg Hennenlotter; Mahmoud Abbas; Ralph Scherer; Thomas Rw Herrmann; Arnulf Stenzl; Markus A Kuczyk; Juergen Serth; Axel S Merseburger Journal: BMC Clin Pathol Date: 2014-04-03